These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19701227)

  • 1. Dialysis: the sweetness of glitazones: randomized trials needed.
    Zoccali C
    Nat Rev Nephrol; 2009 Sep; 5(9):497-8. PubMed ID: 19701227
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential bone effects of thiazolidinediones in diabetic dialysis patients.
    Fourtounas C
    Semin Dial; 2010; 23(5):526; author reply 526. PubMed ID: 21039879
    [No Abstract]   [Full Text] [Related]  

  • 3. Glitazones in chronic kidney disease: potential and concerns.
    Bolignano D; Zoccali C
    Nutr Metab Cardiovasc Dis; 2012 Mar; 22(3):167-75. PubMed ID: 22364889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
    Taylor C; Hobbs FD
    Br J Gen Pract; 2009 Jul; 59(564):520-4. PubMed ID: 19567003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of rhEPO therapy on the protein metabolism of hemodialysis patients with terminal renal insufficiency.
    Fischer C; Scigalla P; Park W; Becker H; Schiller R; Paust H; Broesicke H; Kessel M
    Contrib Nephrol; 1989; 76():250-6. PubMed ID: 2684526
    [No Abstract]   [Full Text] [Related]  

  • 6. Daily dialysis, nocturnal dialysis, and randomized controlled trials: are we asking the right questions?
    Piccoli GB; Magnano A; Perrotta L; Piccoli G
    Kidney Int; 2005 Dec; 68(6):2913-4; author reply 2914. PubMed ID: 16316380
    [No Abstract]   [Full Text] [Related]  

  • 7. Glitazones in type 2 diabetes: an update.
    Drug Ther Bull; 2008 Apr; 46(4):25-9. PubMed ID: 18403615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin in the diabetic patient.
    Friedman EA; Delano BG
    Semin Nephrol; 1990 Mar; 10(2 Suppl 1):35-9. PubMed ID: 2192415
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular mortality in chronic renal failure: hyperphosphatemia, coronary calcification, and the role of phosphate binders.
    Fatica RA; Dennis VW
    Cleve Clin J Med; 2002; 69 Suppl 3():S21-7. PubMed ID: 12086232
    [No Abstract]   [Full Text] [Related]  

  • 10. [The antibacterial therapy of suppurative-septic diseases against a background of kidney failure].
    Ukhin AV
    Antibiot Khimioter; 1991 Jun; 36(6):45-8. PubMed ID: 1898190
    [No Abstract]   [Full Text] [Related]  

  • 11. Convective versus diffusive dialysis therapies for chronic kidney failure: an updated systematic review of randomized controlled trials.
    Nistor I; Palmer SC; Craig JC; Saglimbene V; Vecchio M; Covic A; Strippoli GF
    Am J Kidney Dis; 2014 Jun; 63(6):954-67. PubMed ID: 24434188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The insulin therapy of patients with terminal chronic kidney failure].
    Tychka IB; Petrykiv AV
    Lik Sprava; 1994 Jan; (1):96-9. PubMed ID: 8067036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro: The value of randomized controlled studies in dialysis methods.
    Singh AK; Kari JA; Twardowski ZJ; Misra M
    Nephrol Dial Transplant; 2013 Apr; 28(4):834-5; discussion 835-6. PubMed ID: 23543724
    [No Abstract]   [Full Text] [Related]  

  • 14. [The effect of glitazones on the progression of type 2 diabetes and on cardiovascular endpoints].
    Schatz H
    Dtsch Med Wochenschr; 2005 Aug; 130(31-32):1825-30. PubMed ID: 16052448
    [No Abstract]   [Full Text] [Related]  

  • 15. [Difficult therapy in patients with renal failure. What protects, what damages the kidneys?].
    Stiefelhagen P
    MMW Fortschr Med; 2005 Apr; 147(16):4-6. PubMed ID: 16392389
    [No Abstract]   [Full Text] [Related]  

  • 16. [A computer program for the drug dosage of patients with chronic kidney failure].
    Krivoshiev S; Kalaĭdzhiev Zh; Antonov S; Zlatarska S; Kiriakov Z
    Khirurgiia (Sofiia); 1989; 42(5):108-10. PubMed ID: 2625912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk in uremic patients: darkness after AURORA.
    Robles NR; Macias JF
    Ren Fail; 2010 Jan; 32(2):269-72. PubMed ID: 20199190
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of predialysis patients with recombinant human erythropoietin.
    Koene RA; Frenken LA; Wetzels JF; Sluiter HE; Schrijver G; Verberckmoes R; Michielsen P
    Contrib Nephrol; 1989; 76():242-9. PubMed ID: 2684525
    [No Abstract]   [Full Text] [Related]  

  • 19. Moderator's view: Are alternative dialysis strategies superior to conventional dialysis: what Popper tells us ..
    Van Biesen W; Lameire N
    Nephrol Dial Transplant; 2013 Apr; 28(4):837-8. PubMed ID: 23543725
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
    Czoski-Murray C; Warren E; Chilcott J; Beverley C; Psyllaki MA; Cowan J
    Health Technol Assess; 2004 Apr; 8(13):iii, ix-x, 1-91. PubMed ID: 15038907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.